Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab IPO Summary
Symbiotec Pharmalab IPO DRHP (Draft Red Herring Prospectus) has been Filed With SEBI.
Symbiotec Pharmalab IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Symbiotec Pharmalab IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Jm Financial Ltd, Avendus Capital Pvt Ltd, Motilal Oswal Investment Advisors Ltd, Nomura Financial Advisory & Securities (India) Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Symbiotec Pharmalab Limited DRHP.
Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Symbiotec Pharmalab IPO Reservation
Promoter Holding
Documents
Symbiotec Pharmalab IPO Valuations
Symbiotec Pharmalab Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,598.34 | 1,579.65 | 1,294.79 | 989.99 |
| Total Income | 205.81 | 755.98 | 723.33 | 572.97 |
| Profit After Tax | 29.92 | 96.79 | 100.06 | 23.49 |
| EBITDA | 60.61 | 206.11 | 177.04 | 74.25 |
| NET Worth | 854.43 | 821.15 | 720.68 | 621.17 |
| Reserves and Surplus | 835.26 | 803.77 | 703.91 | 610.50 |
| Total Borrowing | 519.12 | 540.92 | 247.21 | 217.88 |
| Amount in ₹ Crore | ||||
About Symbiotec Pharmalab IPO
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The Company caters to a diversified customer base across domestic and international markets, including regulated and emerging geographies.
Symbiotec follows a research-driven and quality-focused manufacturing approach, with a strong emphasis on regulatory compliance, sustainable processes, and innovation. Its products support pharmaceutical, nutraceutical, and wellness industries, aligning with global quality and safety standards.
With over three decades of industry experience, the Company has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. Symbiotec holds approvals from leading global regulatory authorities, including the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), and the Ministry of Food and Drug Safety, Korea, among others.
As of June 30, 2025, the Company operated two industrial-scale API manufacturing facilities with an aggregate chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres, enabling it to support diversified product development and scalable production.
Through its integrated capabilities, regulatory accreditations, and focus on innovation, Symbiotec Pharmalab Ltd. aims to strengthen its position as a reliable global supplier of high-quality pharmaceutical and nutritional ingredients.
Strength Of Symbiotec Pharmalab IPO
Risk Of Symbiotec Pharmalab IPO
Objectives Symbiotec Pharmalab IPO
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
2. General corporate purposes
Company Contact Details
Symbiotec Pharmalab Ltd. Address
385/2, Pigdamber, Rau, Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/
Registrar Contact Details
Symbiotec Pharmalab FAQs
The Symbiotec Pharmalab IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹2 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.
Quick Links
Comments
